Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
企業コードGNFT
会社名Genfit SA
上場日Dec 19, 2006
最高経営責任者「CEO」Prigent (Pascal)
従業員数180
証券種類Depository Receipt
決算期末Dec 19
本社所在地Parc Eurasante 885 avenue Eugene Avinee
都市LOOS
証券取引所NASDAQ OMX - NASDAQ BASIC
国France
郵便番号59120
電話番号33320164000
ウェブサイトhttps://www.genfit.fr/
企業コードGNFT
上場日Dec 19, 2006
最高経営責任者「CEO」Prigent (Pascal)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし